DE602007012677D1 - Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen - Google Patents
Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungenInfo
- Publication number
- DE602007012677D1 DE602007012677D1 DE602007012677T DE602007012677T DE602007012677D1 DE 602007012677 D1 DE602007012677 D1 DE 602007012677D1 DE 602007012677 T DE602007012677 T DE 602007012677T DE 602007012677 T DE602007012677 T DE 602007012677T DE 602007012677 D1 DE602007012677 D1 DE 602007012677D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- problementation
- iamine
- pyrimidine
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/407,233 US8227455B2 (en) | 2005-04-18 | 2006-04-18 | Methods of treating cell proliferative disorders |
| PCT/US2007/064511 WO2007124221A1 (en) | 2006-04-18 | 2007-03-21 | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007012677D1 true DE602007012677D1 (de) | 2011-04-07 |
Family
ID=38477280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602007012677T Active DE602007012677D1 (de) | 2006-04-18 | 2007-03-21 | Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8227455B2 (https=) |
| EP (1) | EP2010181B1 (https=) |
| JP (1) | JP5204761B2 (https=) |
| AT (1) | ATE499102T1 (https=) |
| CA (1) | CA2649549C (https=) |
| DE (1) | DE602007012677D1 (https=) |
| DK (1) | DK2010181T3 (https=) |
| ES (1) | ES2364657T3 (https=) |
| SI (1) | SI2010181T1 (https=) |
| WO (1) | WO2007124221A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) * | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| UA102825C2 (ru) * | 2007-11-07 | 2013-08-27 | Райджел Фармасьютикалз, Инк. | Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
| JP5603881B2 (ja) * | 2009-01-15 | 2014-10-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼｃ阻害剤とその使用 |
| JP5681723B2 (ja) | 2009-11-20 | 2015-03-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
| CA2792278C (en) | 2010-04-13 | 2019-05-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| ES2689103T3 (es) | 2010-06-30 | 2018-11-08 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| HRP20190186T4 (hr) | 2011-07-28 | 2024-12-20 | Rigel Pharmaceuticals, Inc. | Nove formulacije (trimetoksifenilamino)pirimidinila |
| EP2799431B1 (en) | 2011-12-28 | 2018-01-24 | FUJIFILM Corporation | Novel nicotinamide derivative or salt thereof |
| UY34807A (es) | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| CN103958526B (zh) * | 2012-06-20 | 2015-09-09 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103102412B (zh) * | 2013-01-29 | 2014-03-26 | 陈仁杰 | 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用 |
| WO2016118014A2 (en) * | 2015-01-23 | 2016-07-28 | Erasmus University Medical Center Rotterdam | Anti-senescence compounds and uses thereof |
| JP6833816B2 (ja) * | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| SI3371171T1 (sl) * | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| RU2621187C1 (ru) * | 2016-05-13 | 2017-06-01 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| PE20210096A1 (es) | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| JPWO2023182460A1 (https=) * | 2022-03-24 | 2023-09-28 | ||
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| AU754965B2 (en) * | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| BR0116452A (pt) | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| GEP20074230B (en) * | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| AU2003260344A1 (en) | 2002-08-02 | 2004-02-25 | Vanetta S.P.A. | Redox process particularly for the production of menadione and use of polyoxometalates |
| CA2523125A1 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| SI1814878T1 (sl) | 2004-11-24 | 2012-06-29 | Rigel Pharmaceuticals Inc | Spojine spiro-2,4-pirimidindiamina in njihova uporaba |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20090048214A1 (en) | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
-
2006
- 2006-04-18 US US11/407,233 patent/US8227455B2/en active Active
-
2007
- 2007-03-21 ES ES07759007T patent/ES2364657T3/es active Active
- 2007-03-21 WO PCT/US2007/064511 patent/WO2007124221A1/en not_active Ceased
- 2007-03-21 AT AT07759007T patent/ATE499102T1/de not_active IP Right Cessation
- 2007-03-21 EP EP07759007A patent/EP2010181B1/en active Active
- 2007-03-21 SI SI200730591T patent/SI2010181T1/sl unknown
- 2007-03-21 DK DK07759007.3T patent/DK2010181T3/da active
- 2007-03-21 DE DE602007012677T patent/DE602007012677D1/de active Active
- 2007-03-21 CA CA2649549A patent/CA2649549C/en active Active
- 2007-03-21 JP JP2009506662A patent/JP5204761B2/ja active Active
-
2012
- 2012-06-04 US US13/487,979 patent/US8481521B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007124221A1 (en) | 2007-11-01 |
| ATE499102T1 (de) | 2011-03-15 |
| US8227455B2 (en) | 2012-07-24 |
| US20060276459A1 (en) | 2006-12-07 |
| US8481521B2 (en) | 2013-07-09 |
| SI2010181T1 (sl) | 2011-06-30 |
| DK2010181T3 (da) | 2011-06-14 |
| ES2364657T3 (es) | 2011-09-08 |
| CA2649549A1 (en) | 2007-11-01 |
| US20120245127A1 (en) | 2012-09-27 |
| JP2009534397A (ja) | 2009-09-24 |
| EP2010181A1 (en) | 2009-01-07 |
| CA2649549C (en) | 2011-10-18 |
| JP5204761B2 (ja) | 2013-06-05 |
| EP2010181B1 (en) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007012677D1 (de) | Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen | |
| EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201590230A1 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| IL173722A0 (en) | Proteasome inhibitors and methods of using the same | |
| IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| EA201300171A1 (ru) | Способы и композиции для терапии рака печени | |
| ATE423087T1 (de) | Proteasome inhibitoren und deren verwendung | |
| IL184678A0 (en) | Proteasome inhibitors and methods of using the same | |
| PH12015500181A1 (en) | Atx modulating agents | |
| EA201401212A1 (ru) | Производные пирролотриазинона | |
| MX2012010212A (es) | Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer. | |
| MX2018014577A (es) | Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b. | |
| WO2013112651A3 (en) | Proteasome activity modulating compounds | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MY162518A (en) | Proteasome inhibitors and methods of using the same | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE426605T1 (de) | Inhibitoren von mitotischem kinesin | |
| ATE482218T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors |